Bone Biologics Corp (Bone Biologics) is a biotechnology company which develops orthobiologic products. It develops NELL-1, a recombinant human protein growth factor, which is essential for normal bone development. It offers bone graft substitutes for spine fusion. Bone Biologics also offers NELL-1/DBX fusion device, which is a single dose vial of Nell-1 recombinant protein freeze dried onto tricalcium phosphate and demineralized bone putty. The company's technology has application in spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicines, among others. It collaborates with manufacturing organizations to develop its products. The company markets its products domestic and internationally. Bone Biologics is headquartered in Burlington, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Bone Biologics Corp
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Bone Biologics Corp Company Overview
Bone Biologics Corp Company Snapshot
Bone Biologics Corp Pipeline Products and Ongoing Clinical Trials Overview
Bone Biologics Corp – Pipeline Analysis Overview
Bone Biologics Corp - Key Facts
Bone Biologics Corp - Major Products and Services
Bone Biologics Corp Pipeline Products by Development Stage
Bone Biologics Corp Ongoing Clinical Trials by Trial Status
Mar 01, 2024: Bone Biologics Reports Progress with NB1 Clinical Program
Apr 12, 2023: Bone Biologics gets approval for NB1 bone graft pilot study in Australia
Jan 26, 2023: Bone Biologics advances preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
Mar 07, 2022: Bone Biologics enters into supply agreement with MTF Biologics for demineralized bone matrix
Jan 07, 2020: Bone Biologics preclinical study shows rhNELL-1 effectively promotes bone formation
Mar 25, 2019: Bone Biologics receives Human Research Ethics Committee (HREC) approval for the first center of a multicenter pilot clinical trial to evaluate NB1 (NELL-1/DBX) in Australia
Dec 20, 2017: Bone Biologics: New Preclinical Data For Spine Fusion Demonstrates Osteopromotive Properties
Aug 03, 2017: Bone Biologics Announces Appointment of Bret Hankey to Company’s Board of Director
Jul 06, 2016: Bone Biologics Names Scott D. Boden, MD Chief Medical Advisor
Aug 13, 2015: Bone Biologics Appoints New Chief Executive Officer and a Chief Operating Officer
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: Bone Biologics Corp Pipeline Products and Ongoing Clinical Trials Overview
Table 2: Bone Biologics Corp Pipeline Products by Equipment Type
Table 3: Bone Biologics Corp Pipeline Products by Indication
Table 4: Bone Biologics Corp, Key Facts
Table 5: Bone Biologics Corp, Major Products and Services
Table 6: Bone Biologics Corp Number of Pipeline Products by Development Stage
Table 7: Bone Biologics Corp Pipeline Products Summary by Development Stage
Table 8: Bone Biologics Corp Ongoing Clinical Trials by Trial Status
Table 9: Bone Biologics Corp Ongoing Clinical Trials Summary
Table 10: NB1 Bone Graft - Product Status
Table 11: NB1 Bone Graft - Product Description
Table 12: NB1 Bone Graft - A Multi-center, Prospective, Parallel Group, Randomized, Pilot Study Evaluating Safety and Preliminary Effectiveness of NB1 Bone Graft in Subjects with Degenerative Disc Disease Undergoing Transforaminal Lumbar Interbody Fusion
Table 13: NELL-1/DBX Fusion Device - Osteoporosis - Product Status